In part 5 of the Oncology Value Coalition webinar, experts from City of Hope and Highmark discussed why AccessHope offers an option to payers and oncologists.
While genomic testing has changed the face of cancer care and ensure more informed decision making, designing precision medicine solutions cannot happen if patients lack access to testing, or if tests results are used incorrectly.
In the latest webinar from The American Journal of Managed Care®'s (AJMC®) Oncology Value Coalition, experts from City of Hope and Highmark highlighted the potential of genomic testing, the opportunities that exist through collaboration between academic centers and the private sector, and the barriers that some patients still face.
Joseph Alvarnas, MD, of City of Hope and editor-in-chief of AJMC®'s Evidence-Based Oncology™, moderated a discussion with:
In segment 5, panelists discuss why AccessHope offers an option to payers and oncologists.
HIVconsvX Vaccine Shows Safety, Immune Response in People on ART
March 10th 2025This research on a T-cell–targeting vaccines in HIV has implications for future study design to incorporate consideration of age and years on antiretroviral therapy (ART) to evaluate the level of immune reconstitution.
Read More
Politics vs Science: The Future of US Public Health
February 4th 2025On this episode of Managed Care Cast, we speak with Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, on the public health implications of the US withdrawal from the World Health Organization and the role of public health leaders in advocating for science and health.
Listen
Ruxolitinib Cream Shows Long-Term Safety in AD, Potential for PN Treatment
March 8th 2025Two posters presented at the 2025 American Academy of Dermatology Annual Meeting reaffirmed the impact of ruxolitinib cream (Opzelura; Incyte) in atopic dermatitis (AD), while late-breaking research highlighted its potential efficacy in prurigo nodularis (PN).
Read More